SingVax Merges With Inviragen To Raise $15 Million In Series-A Financing For Vaccines To Fight Infectious Disease
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - U.S.-based Inviragen and Singapore-based SingVax unveiled plans to merge their companies' vaccine pipelines to form a new entity known as Inviragen (Singapore) to develop vaccines for a range of infectious diseases including dengue fever, Japanese encephalitis and hand, foot and mouth disease
You may also be interested in...
Inviragen Finds New Life For Shelved Japanese Encephalitis Vaccine At State-Owned VABIOTECH
A vaccine project put on the shelf – after better-funded Intercell won regulatory approval for a rival product – has found a new home in Vietnam at a state-owned company looking to keep costs in check.
Asia Innovators: Singapore's Inviragen In Race With Sinovac For HFMD Vaccine
SINGAPORE - Inviragen (Singapore) Pte Ltd is recruiting patients for its Phase I clinical trial in Singapore for its hand, foot and mouth disease vaccine INV21
Asia Innovators: Singapore's Inviragen In Race With Sinovac For HFMD Vaccine
SINGAPORE - Inviragen (Singapore) Pte Ltd is recruiting patients for its Phase I clinical trial in Singapore for its hand, foot and mouth disease vaccine INV21